Herman Waldmann

Q: What Schools Are Affiliated With Herman Waldmann

Herman Waldmann is affiliated with the following schools: University of Oxford, Royal Postgraduate Medical School, University of Cambridge

Herman Waldmann's AcademicInfluence.com Rankings

Herman Waldmann

Biology

#1783

World Rank

#2898

Historical Rank

Immunology

#101

World Rank

#107

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Herman Waldmann Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Herman Waldmann FRS FMedSci is a British immunologist known for his work on therapeutic monoclonal antibodies. As of 2013, he is Emeritus Professor of Pathology at the Sir William Dunn School of Pathology at the University of Oxford.

(See a Problem?)

Herman Waldmann's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Reshaping human antibodies for therapy (1988) (1597)
"Infectious" transplantation tolerance (1993) (919)
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. (2005) (909)
Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo (1984) (906)
Regulatory T cells in transplantation tolerance. (2005) (808)
Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies (1987) (633)
Identification of Regulatory T Cells in Tolerated Allografts (2002) (619)
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells (1989) (601)
REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H (1988) (578)
Plasticity of Foxp3(+) T cells reflects promiscuous Foxp3 expression in conventional T cells but not reprogramming of regulatory T cells. (2012) (544)
Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). (2002) (542)
Heterogeneity of natural Foxp3+ T cells: A committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity (2009) (539)
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. (1990) (533)
In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. (2000) (530)
Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis (1999) (500)
The window of therapeutic opportunity in multiple sclerosis (2005) (496)
The plasticity and stability of regulatory T cells (2013) (459)
Prope tolerance, perioperative campath 1H, and low-dose cyclosporin monotherapy in renal allograft recipients (1998) (443)
Induction of foxP3+ Regulatory T Cells in the Periphery of T Cell Receptor Transgenic Mice Tolerized to Transplants1 (2004) (442)
Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis (1999) (440)
Bone marrow transplantation for patients with chronic myeloid leukemia. (1986) (407)
Both CD4+CD25+ and CD4+CD25− Regulatory Cells Mediate Dominant Transplantation Tolerance1 (2002) (403)
Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells (2003) (388)
Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. (1983) (376)
ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1) (1984) (365)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. (2002) (362)
Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. (2002) (361)
Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. (1989) (357)
Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance (1986) (349)
Induction of classical transplantation tolerance in the adult (1989) (331)
The CAMPATH-1 antigen (CDw52). (1990) (326)
Infectious tolerance via the consumption of essential amino acids and mTOR signaling (2009) (321)
Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse. (1986) (313)
Induction of tolerance in peripheral T cells with monoclonal antibodies (1990) (305)
Impaired resistance to Mycobacterium tuberculosis infection after selective in vivo depletion of L3T4+ and Lyt-2+ T cells (1987) (303)
Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass (2010) (302)
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. (2004) (302)
Humanised monoclonal antibody therapy for rheumatoid arthritis (1992) (301)
Induction of tolerance by monoclonal antibody therapy (1986) (301)
Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. (1999) (300)
Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis (2005) (294)
IL-10 Gene Expression Is Controlled by the Transcription Factors Sp1 and Sp31 (2000) (292)
Limiting Dilution Analysis of Cells in the Immune System (1980) (291)
CD40 ligand blockade induces CD4+ T cell tolerance and linked suppression. (1999) (289)
Regulating the immune response to transplants. a role for CD4+ regulatory cells? (2001) (275)
Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation (2005) (273)
Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as C1q (1988) (267)
T cell suppression in transplantation tolerance through linked recognition. (1996) (267)
Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. (1996) (261)
Activated regulatory T cells are the major T cell type emigrating from the skin during a cutaneous immune response in mice. (2010) (256)
Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells. (2005) (256)
In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. (1995) (253)
Functional analysis of T lymphocyte subsets in antiviral host defense. (1987) (248)
Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. (1996) (236)
How do monoclonal antibodies induce tolerance? A role for infectious tolerance? (1998) (235)
Different roles for L3T4+ and Lyt 2+ T cell subsets in the control of an acute herpes simplex virus infection of the skin and nervous system. (1987) (232)
Cutting Edge: Anti-CD154 Therapeutic Antibodies Induce Infectious Transplantation Tolerance1 (2000) (231)
Monoclonal-antibody therapy in systemic vasculitis. (1990) (229)
Alemtuzumab (CAMPATH 1H) Induction Therapy in Cadaveric Kidney Transplantation—Efficacy and Safety at Five Years (2005) (221)
Limiting dilution analysis of the cells of immune system I. The clonal basis of the immune response. (1984) (214)
The generation of a humanized, non‐mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties (1993) (210)
Mechanisms of Peripheral Tolerance and Suppression Induced by Monoclonal Antibodies to CD4 and CD8 (1996) (208)
Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. (1993) (207)
Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy (1993) (206)
Mechanism of recovery from acute virus infection: treatment of lymphocytic choriomeningitis virus-infected mice with monoclonal antibodies reveals that Lyt-2+ T lymphocytes mediate clearance of virus and regulate the antiviral antibody response (1987) (206)
Monocytic origin of foam cells in human atherosclerotic plaques. (1984) (206)
Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. (1998) (203)
Linked suppression of skin graft rejection can operate through indirect recognition. (1998) (199)
Posttranscriptional Regulation of IL-10 Gene Expression Through Sequences in the 3′-Untranslated Region1 (2000) (198)
Manipulation of T-cell responses with monoclonal antibodies. (1989) (195)
Embryonic stem cell-derived tissues are immunogenic but their inherent immune privilege promotes the induction of tolerance (2007) (193)
Regulatory T cells and organ transplantation. (2004) (193)
Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance (2011) (192)
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration. (2004) (189)
Dominant transplantation tolerance impairs CD8+ T cell function but not expansion (2002) (189)
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. (1991) (188)
Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies (1985) (187)
Regulation of IL-18 (IFN-gamma-inducing factor) gene expression. (1997) (186)
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis (1994) (184)
CD4 monoclonal antibody pairs for immunosuppression and tolerance induction (1987) (184)
Mechanisms in CD4 antibody‐mediated transplantation tolerance: kinetics of induction, antigen dependency and role of regulatory T cells (1994) (182)
T CELL DEPLETION WITH CAMPATH‐1 IN ALLOGENEIC BONE MARROW TRANSPLANTATION (1988) (179)
The effect of treatment with Campath‐1H in patients with autoimmune cytopenias (2001) (175)
The immunogenicity of chimeric antibodies (1989) (174)
Amplification of natural regulatory immune mechanisms for transplantation tolerance. (1996) (174)
Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. (1998) (171)
The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells (2011) (170)
The induction of skin graft tolerance in major histocompatibility complex‐mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti‐CD4 and anti‐CD8 antibodies (1990) (169)
Characterization of the CAMPATH‐1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone (1991) (168)
Infectious tolerance and the long‐term acceptance of transplanted tissue (2006) (163)
Rejection of H-Y disparate skin grafts by monospecific CD4+ Th1 and Th2 cells: no requirement for CD8+ T cells or B cells. (1998) (163)
T‐cell‐depleted allogeneic bone marrow transplantation for acute leukaemia using Campath‐1 antibodies and post‐transplant administration of donor's peripheral blood lymphocytes for prevention of relapse (1995) (162)
CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells (2000) (161)
Accelerated Memory Cell Homeostasis during T Cell Depletion and Approaches to Overcome It (2006) (160)
Tolerance to rat monoclonal antibodies. Implications for serotherapy (1986) (159)
IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES (1988) (157)
T cell regulation in adult transplantation tolerance. (1996) (156)
Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission (1996) (155)
Directed differentiation of dendritic cells from mouse embryonic stem cells (2000) (153)
Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β (2011) (150)
Regulatory T Cells Overexpress a Subset of Th2 Gene Transcripts1 (2002) (146)
Regulation of CD40 function by its isoforms generated through alternative splicing. (2001) (144)
Activated polyamidoamine dendrimers, a non-viral vector for gene transfer to the corneal endothelium (1999) (144)
Immune privilege induced by regulatory T cells in transplantation tolerance (2006) (141)
A repertoire of monoclonal antibodies with human heavy chains from transgenic mice. (1989) (139)
Phase I study of an engineered aglycosylated humanized CD3 antibody in renal transplant rejection. (1999) (139)
Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms (2003) (138)
CD73 and adenosine generation in the creation of regulatory microenvironments (2013) (138)
Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. (1996) (137)
Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. (1985) (132)
The role of CD4+ T‐cell subsets in determining transplantation rejection or tolerance (2001) (131)
Tolerance in the mouse to major histocompatibility complex‐mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8 (1992) (130)
Structural motifs involved in human IgG antibody effector functions (1993) (127)
Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. (1998) (124)
Infectious tolerance. (1998) (123)
Reprogramming the Immune System for Peripheral Tolerance with CD4 and CD8 Monoclonal Antibodies (1992) (122)
Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. (2017) (121)
Skin allograft rejection by L3/T4+ and Lyt-2+ T cell subsets. (1986) (119)
Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. (1993) (119)
Donor-specific transplantation tolerance: the paradoxical behavior of CD4+CD25+ T cells. (2004) (118)
Mechanisms of monoclonal antibody‐facilitated tolerance induction: a possible role for the CD4 (L3T4) and CD11a (LFA‐1) molecules in self‐non‐self discrimination (1988) (116)
The use of a non‐depleting anti‐CD4 monoclonal antibody to re‐establish tolerance to β cells in NOD mice (1992) (115)
CAMPATH: from concept to clinic (2005) (114)
Campath-1H therapy in refractory ocular inflammatory disease (2000) (114)
The human interleukin 18 gene IL18 maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and distinct from mapped IDDM loci. (1998) (110)
The Role of Lipid Metabolism in T Lymphocyte Differentiation and Survival (2018) (109)
Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. (1995) (108)
Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. (1998) (107)
Dendritic cells and prospects for transplantation tolerance. (2000) (106)
Requirements for the promotion of allogeneic engraftment by anti-CD154 (anti-CD40L) monoclonal antibody under nonmyeloablative conditions. (2001) (102)
Generation of Anergic and Regulatory T Cells following Prolonged Exposure to a Harmless Antigen 1 (2004) (99)
Incidence and outcome of adenovirus disease in transplant recipients after reduced-intensity conditioning with alemtuzumab. (2004) (98)
Expression of murine IL-12 is regulated by translational control of the p35 subunit. (1999) (97)
Tolerance and suppression in a primed immune system. (1996) (97)
Control of graft-versus-host disease and graft rejection by T cell depletion of donor and recipient with Campath-1 antibodies. Results of matched sibling transplants for malignant diseases. (1994) (96)
Induction of Regulatory T Cells and Dominant Tolerance by Dendritic Cells Incapable of Full Activation1 (2007) (96)
In vivo‘Purging’ of residual disease in CLL with Campath‐1H (1997) (95)
mTOR signalling and metabolic regulation of T cell differentiation. (2010) (94)
Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. (2003) (92)
A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20 krad-irradiated and Ro 11-3128-terminated infections. (1989) (91)
Transplantation tolerance—where do we stand? (1999) (91)
Critical Influence of Natural Regulatory CD25+ T Cells on the Fate of Allografts in the Absence of Immunosuppression (2005) (91)
Self tolerance is H–2-restricted (1984) (90)
Reshaping a therapeutic CD4 antibody. (1991) (88)
Therapeutic potential of monovalent monoclonal antibodies (1984) (85)
Structure and chromosomal location of the mouse interleukin‐12 p35 and p40 subunit genes (1996) (84)
Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality (2002) (83)
Alopecia areata: Animal models illuminate autoimmune pathogenesis and novel immunotherapeutic strategies. (2016) (82)
Immunoglobulin heavy chain locus of the rat: striking homology to mouse antibody genes. (1986) (82)
The vaccinia virus C12L protein inhibits mouse IL-18 and promotes virus virulence in the murine intranasal model. (2002) (82)
Exploiting Tolerance Processes in Transplantation (2004) (82)
Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. (2001) (82)
Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. (1990) (80)
Children with acute lymphoblastic leukemia who receive T-cell-depleted HLA mismatched marrow allografts from unrelated donors have an increased incidence of primary graft failure but a similar overall transplant outcome. (1999) (80)
Connecting the mechanisms of T‐cell regulation: dendritic cells as the missing link (2010) (79)
CAMPATH-1 monoclonal antibodies in bone marrow transplantation. (1994) (78)
A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. (1981) (78)
Transient Epstein-Barr virus reactivation in CD3 monoclonal antibody-treated patients. (2010) (77)
A Key Role for TGF-β Signaling to T Cells in the Long-Term Acceptance of Allografts1 (2007) (77)
In Vivo Kinetics of GITR and GITR Ligand Expression and Their Functional Significance in Regulating Viral Immunopathology (2005) (75)
Ex vivo T‐cell depletion with the monoclonal antibody Campath‐1 plus human complement effectively prevents acute graft‐versus‐host disease in allogeneic bone marrow transplantation (1986) (74)
IL-10-Conditioned Dendritic Cells, Decommissioned for Recruitment of Adaptive Immunity, Elicit Innate Inflammatory Gene Products in Response to Danger Signals1 (2004) (73)
Elimination of the immunogenicity of therapeutic antibodies. (1999) (73)
Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential. (1992) (73)
Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM–CAMPATH conditioning: an effective regimen with low procedure‐related toxicity (2000) (72)
TGF-β–Mediated Foxp3 Gene Expression Is Cooperatively Regulated by Stat5, Creb, and AP-1 through CNS2 (2014) (72)
Embryonic stem cells and the challenge of transplantation tolerance. (2004) (71)
Reactivity of rat monoclonal antibody CAMPATH‐1 with human leukaemia cells and its possible application for autologous bone marrow transplantation (1985) (70)
T Cell-dependent Mediator in the Immune Response (1973) (70)
Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. (1996) (70)
CD66 identifies a neutrophil-specific epitope within the hematopoietic system that is expressed by members of the carcinoembryonic antigen family of adhesion molecules. (1991) (70)
A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans (1996) (69)
Enhanced Production of IL-10 by Dendritic Cells Deficient in CIITA1 (2005) (69)
Dominant tolerance: activation thresholds for peripheral generation of regulatory T cells. (2005) (68)
The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukaemia (2000) (68)
Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. (2000) (68)
Isolation of low-frequency class-switch variants from rat hybrid myelomas. (1987) (67)
A Novel Strategy To Reduce the Immunogenicity of Biological Therapies (2010) (67)
Tmem176B and Tmem176A are associated with the immature state of dendritic cells (2010) (67)
Resistance to experimental autoimmune thyroiditis: L3T4+ cells as mediators of both thyroglobulin-activated and TSH-induced suppression. (1989) (67)
Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells (2007) (66)
Neutralizing tumor necrosis factor activity leads to remission in patients with refractory noninfectious posterior uveitis. (2004) (66)
The Role of Sp1 and NF-κB in Regulating CD40 Gene Expression* (2002) (65)
Reconstitution of the Epstein-Barr virus-specific cytotoxic T-lymphocyte response following T-cell-depleted myeloablative and nonmyeloablative allogeneic stem cell transplantation. (2003) (64)
Generation of immunogenic dendritic cells from human embryonic stem cells without serum and feeder cells. (2009) (63)
EFFECT OF GRAFT PERFUSION WITH TWO CD45 MONOCLONAL ANTIBODIES ON INCIDENCE OF KIDNEY ALLOGRAFT REJECTION (1989) (63)
A matched set of rat/mouse chimeric antibodies. Identification and biological properties of rat H chain constant regions mu, gamma 1, gamma 2a, gamma 2b, gamma 2c, epsilon, and alpha. (1989) (63)
Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. (1986) (62)
Conditions Determining the Generation and Expression of T Helper Cells (1977) (62)
Beneficial effect of monoclonal antibody to interleukin 2 receptor on activated T cells in rheumatoid arthritis. (1989) (62)
Successful attenuation of humoral immunity to viral capsid and transgenic protein following AAV-mediated gene transfer with a non-depleting CD4 antibody and cyclosporine (2011) (61)
Embryonic stem cells: overcoming the immunological barriers to cell replacement therapy. (2009) (60)
Alemtuzumab (CAMPATH-1H) for the Treatment of Acute Rejection in Kidney Transplant Recipients: Long-Term Follow-Up (2009) (59)
Classical transplantation tolerance in the adult: the interaction between myeloablation and immunosuppression (1992) (59)
Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies (1993) (58)
A humanized monovalent CD3 antibody which can activate homologous complement (1991) (58)
Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. (1983) (58)
The Influence of the Major Histocompatibility Complex on the Function of T‐Helper Cells in Antibody Formation (1978) (58)
Therapy with monoclonal antibodies. II. The contribution of Fc gamma receptor binding and the influence of C(H)1 and C(H)3 domains on in vivo effector function. (1998) (58)
Campath-1M--prophylactic use after kidney transplantation. A randomized controlled clinical trial. (1989) (58)
T‐cell depletion with Campath‐1H ‘in the bag’ for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft‐versus‐host disease, rapid immune constitution and improved survival (2003) (58)
T-cell killing of target cells induced by hybrid antibodies: comparison of two bispecific monoclonal antibodies. (1987) (58)
The use of monoclonal antibodies to achieve immunological tolerance. (1993) (57)
Influence of the major histocompatibility complex on lymphocyte interactions in antibody formation (1978) (57)
Immune reconstitution at 6 months following t-cell depleted hematopoietic stem cell transplantation is predictive for treatment outcome (2002) (57)
Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. (1989) (56)
Favorable effect on acute and chronic graft-versus-host disease with cyclophosphamide and in vivo anti-CD52 monoclonal antibodies for marrow transplantation from HLA-identical sibling donors for acquired aplastic anemia. (2004) (55)
Humanized anti‐CD4 monoclonal antibody therapy of autoimmune and inflammatory disease (1997) (54)
CAMPATH‐1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura (1993) (54)
Do L3T4+ T cells act as effector cells in protection against influenza virus infection. (1987) (54)
TGF-β in transplantation tolerance. (2011) (54)
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. (2001) (54)
Human CD3 Transgenic Mice: Preclinical Testing of Antibodies Promoting Immune Tolerance (2011) (53)
Harnessing FOXP3+ regulatory T cells for transplantation tolerance. (2014) (53)
The Depletion of T Cell Subsets in Vitro and in Vivo (1986) (53)
Monoclonal antibodies as agents to reinduce tolerance in autoimmunity. (1992) (53)
Limiting dilution analysis of helper T-cell function. (1975) (53)
Multiterminal Operation of HVDC Converter Stations (1969) (52)
The involvement of Ly2+ T cells in beta cell destruction. (1990) (52)
Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection. (1999) (52)
Removal of T cells from bone marrow for transplantation. Comparison of rat monoclonal anti-lymphocyte antibodies of different isotypes. (1983) (51)
Pathogenic mechanisms in murine autoimmune thyroiditis: short- and long-term effects of in vivo depletion of CD4+ and CD8+ cells. (1989) (51)
T‐ and B‐cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T‐cell‐depleted, reduced‐intensity allogeneic stem cell transplantation with an alemtuzumab‐containing conditioning regimen followed by escalated donor lymphocyte infusions (2003) (51)
Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H. (1995) (50)
A Role for Regulatory T Cells in Acceptance of ESC‐Derived Tissues Transplanted Across an Major Histocompatibility Complex Barrier (2010) (50)
Reversal of allograft rejection using the monoclonal antibody, Campath-1G. (1991) (50)
THE EFFECT OF AGLYCOSYLATION ON THE IMMUNOGENICITY OF A HUMANIZED THERAPEUTIC CD3 MONOCLONAL ANTIBODY (1995) (49)
Expansion of Foxp3+ T-cell populations by Candida albicans enhances both Th17-cell responses and fungal dissemination after intravenous challenge (2014) (49)
Nutrient Sensing via mTOR in T Cells Maintains a Tolerogenic Microenvironment (2014) (49)
Regulatory T Cells Promote Apelin-Mediated Sprouting Angiogenesis in Type 2 Diabetes. (2018) (49)
Advantages of rat monoclonal antibodies. (1983) (49)
Infectious tolerance: therapeutic potential. (2010) (48)
Dominant transplantation tolerance. Opinion. (2003) (48)
Fas-independent apoptosis of activated T cells induced by antibodies to the HLA class I alpha1 domain. (1997) (48)
Structural basis for ligand-mediated mouse GITR activation (2008) (48)
T cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. (1994) (48)
A personal history of the CAMPATH-1H antibody (2002) (48)
Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning? (2002) (46)
MS4A4B Is a GITR-Associated Membrane Adapter, Expressed by Regulatory T Cells, Which Modulates T Cell Activation1 (2009) (46)
Regulatory T cells in the induction and maintenance of peripheral transplantation tolerance (2003) (46)
Ex vivo depletion of T cells from bone marrow grafts with CAMPATH-1 in acute leukemia: graft-versus-host disease and graft-versus-leukemia effect. (1999) (46)
The improved lytic function and in vivo efficacy of monovalent monoclonal CD3 antibodies (1989) (45)
CAMPATH-1 antibodies in stem-cell transplantation. (2001) (45)
Limiting dilution analysis of cells of the immune system II: What can be learnt? (1984) (45)
Induction of Immunological Tolerance/Hyporesponsiveness in Baboons with a Nondepleting CD4 Antibody (2004) (45)
T cell depletion of human bone marrow. Comparison of Campath-1 plus complement, anti-T cell ricin A chain immunotoxin, and soybean agglutinin alone or in combination with sheep erythrocytes or immunomagnetic beads. (1989) (45)
1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen. (1999) (44)
Active suppression induced by anti‐CD4 (1993) (44)
Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes. (2008) (44)
Peripheral tolerance mechanisms prevent the development of autoreactive T cells in chimeras grafted with two minor incompatible thymuses (1989) (44)
Reprogramming the immune system for tolerance with monoclonal antibodies. (1990) (44)
Cell-surface markers on haemopoietic precursors. Reagents for the isolation and analysis of progenitor cell subpopulations. (1987) (44)
Sustained remission of severe resistant autoimmune neutropenia with Campath‐1H (1997) (43)
From Laboratory to Clinic : The Story of CAM PA TH-1. (2000) (43)
A role for Th2 cytokines in the suppression of CD8+ T cell‐mediated graft rejection (1997) (43)
L3T4 and Lyt-2 T cells are both involved in the generation of low-dose streptozotocin-induced diabetes in mice. (1987) (43)
Cooperation across the histocompatibility barrier (1975) (42)
Gene structure of human CD59 and demonstration that discrete mRNAs are generated by alternative polyadenylation. (1992) (42)
Regulatory T cells in transplantation. (2006) (42)
Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H (1995) (42)
Key Role of the GITR/GITRLigand Pathway in the Development of Murine Autoimmune Diabetes: A Potential Therapeutic Target (2009) (42)
Induction of dominant transplantation tolerance by an altered peptide ligand of the male antigen Dby. (2004) (42)
The influence of thymus on the development of MHC restrictions exhibited by T-helper cells (1979) (41)
THE REPOPULATION CAPACITY OF BONE MARROW GRAFTS FOLLOWING PRETREATMENT WITH MONOCLONAL ANTIBODIES AGAINST T LYMPHOCYTES IN RHESUS MONKEYS (1988) (41)
Human Monoclonal Antibodies: The Benefits of Humanization. (2018) (40)
Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: effect of stem cell source on short- and long-term outcome (2001) (39)
Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. (1986) (39)
Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization (2018) (39)
CD8+ Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus (2005) (39)
THERAPEUTIC POTENTIAL OF MONOCLONAL ANTIBODIES TO THE LEUKOCYTE‐COMMON ANTIGEN: SYNERGY AND INTERFERENCE IN COMPLEMENT‐MEDIATED LYSIS (1985) (39)
Tolerance: an overview and perspectives (2010) (39)
Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. (1996) (38)
Dominant Transplantation Tolerance (2001) (38)
The major histocompatibility system and the immune response. (1978) (38)
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia. (2006) (38)
Pharmacokinetics and Antibody Responses to the CD3 Antibody Otelixizumab Used in the Treatment of Type 1 Diabetes (2010) (38)
Anti-adhesion molecule therapy as an interventional strategy for autoimmune inflammation. (1999) (37)
Reprogramming the immune system: co‐receptor blockade as a paradigm for harnessing tolerance mechanisms (2008) (37)
Therapeutic approaches for transplantation. (2001) (36)
Regulatory cells and transplantation tolerance. (2013) (36)
The relationship between pityriasis rubra pilaris and inflammatory arthritis: case report and response of the arthritis to anti-tumor necrosis factor immunotherapy. (1999) (36)
Foxp3+ T reg cells control psoriasiform inflammation by restraining an IFN-I–driven CD8+ T cell response (2018) (36)
Immunology: Protection and privilege (2006) (36)
Serial analysis of gene expression provides new insights into regulatory T cells. (2003) (36)
Strain variation in susceptibility to monoclonal antibody-induced transplantation tolerance. (1997) (35)
Dickkopf-3, a Tissue-Derived Modulator of Local T-Cell Responses (2015) (35)
Foxp3 Expression Is Required for the Induction of Therapeutic Tissue Tolerance (2012) (35)
T cell-dependent mediator in the immune response. III. The role of non-specific factor (NSF) in the in vitro immune response. (1975) (35)
The CD59 antigen--a multifunctional molecule. (1992) (35)
Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. (1998) (34)
Regulation and Privilege in Transplantation Tolerance (2008) (34)
Loss of the TGFβ-Activating Integrin αvβ8 on Dendritic Cells Protects Mice from Chronic Intestinal Parasitic Infection via Control of Type 2 Immunity (2013) (34)
The use of monoclonal antibodies to achieve immunological tolerance. (1993) (33)
CAMPATH-1H in multiple sclerosis (1996) (33)
Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype. (1995) (33)
Prope tolerance with induction using Campath 1H and low-dose cyclosporin monotherapy in 31 cadaveric renal allograft recipients. (2000) (33)
The failure to show a necessary role for C3 in the in vitro antibody response (1975) (32)
Suppression in murine experimental autoimmune thyroiditis: in vivo inhibition of CD4+ T cell-mediated resistance by a nondepleting rat CD4 monoclonal antibody. (1991) (32)
PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA BY T-CELL DEPLETION INVITRO PRIOR TO TRANSPLANTATION (1985) (32)
Immunohistological screening in the selection of monoclonal antibodies: the use of isotype-specific antiglobulins. (1984) (32)
Complement activation by immunoglobulin does not depend solely on C1q binding (1990) (32)
In vivo use of Campath-1G to prevent graft-versus-host disease and graft rejection after bone marrow transplantation. (1992) (31)
Excessive T cell depletion of peripheral blood stem cells has an adverse effect upon outcome following allogeneic stem cell transplantation (2001) (31)
Transfection of human CD59 complementary DNA into rat cells confers resistance to human complement (1991) (31)
Hybrid antibodies for therapy. (1988) (31)
Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here? (2004) (30)
Partial and transient modulation of the CD3–T‐cell receptor complex, elicited by low‐dose regimens of monoclonal anti‐CD3, is sufficient to induce disease remission in non‐obese diabetic mice (2010) (30)
Thomas' hematopoietic cell transplantation (2005) (30)
A Novel Role for Triglyceride Metabolism in Foxp3 Expression (2019) (30)
Universal bispecific antibody for targeting tumor cells for destruction by cytotoxic T cells. (1988) (30)
Resistance of regulatory T cells to glucocorticoid‐viduced TNFR family‐related protein (GITR) during Plasmodium yoelii infection (2005) (30)
Monoclonal antibodies for the induction of transplantation tolerance. (1993) (30)
Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis. (1994) (29)
Embryonic stem cells: protecting pluripotency from alloreactivity. (2007) (29)
Exacerbation of delayed-type hypersensitivity responses in EBV-induced gene-3 (EBI-3)-deficient mice. (2010) (29)
Dominant tolerance and linked suppression induced by therapeutic antibodies do not depend on Fas-FasL interactions. (2000) (29)
Apoptosis: potential for disease therapies. (1998) (29)
Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. (2015) (28)
Co-receptor and co-stimulation blockade for mixed chimerism and tolerance without myelosuppressive conditioning (2006) (28)
T cell-dependent mediator in the immune response. II. Physical and biological properties. (1974) (28)
CD4 T cells can reject major histocompatibility complex class I‐incompatible skin grafts (1999) (28)
Embryonic stem cells: a novel source of dendritic cells for clinical applications. (2005) (28)
Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells (2018) (28)
Fc‐Disabled Anti‐Mouse CD40L Antibodies Retain Efficacy in Promoting Transplantation Tolerance (2008) (28)
Tolerance induction to human stem cell transplants with extension to their differentiated progeny (2014) (28)
Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies. (1999) (27)
Enhancement of humoral and cellular immunity with an anti‐glucocorticoid‐induced tumour necrosis factor receptor monoclonal antibody (2010) (27)
Prevention of diabetes but not insulitis in NOD mice injected with antibody to CD4. (1993) (27)
Enhanced murine contact hypersensitivity by depletion of endogenous regulatory T cells in the sensitization phase. (2011) (27)
Tolerance induction in the adult using monoclonal antibodies to CD4, CD8, and CD11a (LFA-1). (1989) (26)
The role of Sp1 and NF-kappa B in regulating CD40 gene expression. (2002) (26)
Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. (1996) (25)
Tolerance can be infectious (2008) (25)
Restriction in the function of single helper T cells. (1976) (24)
Semi-specific immuno-absorption and monoclonal antibody therapy in ANCA positive vasculitis: experience in four cases. (1998) (24)
Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. (1995) (24)
A Theoretical Framework for Self-tolerance and its Relevance to Therapy of Autoimmune Disease (1988) (24)
Antigen-non-specific T-cell factor in B-cell activation. Origin, biological properties and failure to show a relationship to H-2. (1976) (24)
Stable lines of genetically modified dendritic cells from mouse embryonic stem cells (2003) (24)
Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH‐I monoclonal antibody and E‐rosetting (1986) (24)
Tolerance to IDDM Induced by CD4 Antibodies in Nonobese Diabetic Mice is Reversed by Cyclophosphamide (1993) (24)
Ectopic transplantation of tissues under the kidney capsule. (2007) (23)
Monogamous T helper cell (1977) (23)
T cell sensitivity to HLA class I‐mediated apoptosis is dependent on interleukin‐2 and interleukin‐4 (1997) (23)
The Induction and Maintenance of Transplant Tolerance Engages Both Regulatory and Anergic CD4+ T cells (2017) (23)
Separation of hemopoietic cells from adult mouse marrow by use of monoclonal antibodies. (1983) (23)
Resistance to collagen-induced arthritis in DBA/1 mice by intraperitoneal administration of soluble type II collagen involves both CD4+ and CD8+ T lymphocytes. (1989) (23)
The anti-IL-2 receptor monoclonal antibody YTH-906 in liver transplantation. (1991) (22)
Effect of CD4 monoclonal antibody in vivo on lesion development, delayed-type hypersensitivity and interleukin 3 production in experimental murine cutaneous leishmaniasis. (1989) (22)
Properties of educated T cells. The ability of educated T cells to facilitate the immune response to non‐cross‐reacting antigens in vitro (1973) (22)
Reprogramming the immune system (2002) (22)
Antibody-induced transplantation tolerance (2003) (22)
Delay in onset of insulitis in NOD mice following a single injection of CD 4 and CD 8 antibodies. (1988) (22)
Autologous transplantation with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia: long-term follow-up. (1996) (21)
Heterogeneity of B cells reacting with T-cell factors. Evidence for matching T-cell and B-cell subsets. (1976) (21)
CD8+ T‐Cell Depletion and Rapamycin Synergize with Combined Coreceptor/Stimulation Blockade to Induce Robust Limb Allograft Tolerance in Mice (2008) (21)
Immunosuppression with monoclonal antibodies. A model to determine the rules for effective serotherapy. (1983) (21)
Humanized monoclonal antibody treatment in rheumatoid arthritis. (1991) (21)
Mechanisms of antibody immunotherapy on clonal islet reactive T cells. (2006) (21)
Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G. (2000) (21)
Biomarkers of Transplantation Tolerance: More Hopeful than Helpful? (2011) (21)
Optimism after much pessimism: what next? (1999) (21)
BLOCKING OF CYTOTOXIC T CELL FUNCTION BY MONOCLONAL ANTIBODIES AGAINST THE CD45 ANTIGEN (T200/LEUKOCYTE‐COMMON ANTIGEN (1987) (20)
Limiting dilution analysis of helper T-cell function. II. An approach to the study of the function of single helper T cells. (1976) (20)
Structure and chromosomal location of mouse and human CD52 genes. (1999) (20)
Tolerogenicity is not an absolute property of a dendritic cell (2010) (20)
DELAYED ALLOGRAFT REJECTION IN PRIMATES TREATED WITH ANTI‐IL-2 RECEPTOR MONOCLONAL ANTIBODY CAMPATH‐6 (1988) (20)
Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts (2005) (19)
Depletion of CD4+ and CD8+ cells eliminates immunologic memory of thyroiditogenicity in murine experimental autoimmune thyroiditis. (1994) (19)
The characterisation of monoclonal antibodies against haemopoietic cells: comparison of an immunoperoxidase method with fluorescence activated cell sorting. (1983) (19)
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS (1992) (18)
High Level Transcription of the Complement Regulatory Protein CD59 Requires an Enhancer Located in Intron 1* (1999) (18)
Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience. (2004) (18)
Secreted and Transmembrane 1A Is a Novel Co-Stimulatory Ligand (2013) (18)
Helplessness as a strategy for avoiding antiglobulin responses to therapeutic monoclonal antibodies. (1994) (18)
Th17 Cells Induce a Distinct Graft Rejection Response That Does Not Require IL‐17A (2012) (18)
The potential of hybrid antibodies secreted by hybrid‐hybridomas in tumour therapy (1988) (17)
Therapeutic aspects of tolerance. (2001) (17)
The development of insulin-dependent diabetes mellitus in non-obese diabetic mice: the role of CD4+ and CD8+ T cells. (1991) (17)
A humanised therapeutic CD4 mAb inhibits TCR-induced IL-2, IL-4, and IL-10 secretion and expression of CD25, CD40L, and CD69. (1998) (17)
CAMPATH-1H in inflammatory arthritis. (1993) (17)
Regulatory T cells and transplantation tolerance. (2008) (17)
Low dose unresponsiveness with a thymus independent antigen (1975) (16)
The new immunosuppression. (2003) (16)
Cooperation across the histocompatibility barrier: H2d T cells primed to antigen in an H-2d environment can cooperate with H-2k B cells (1976) (16)
Antilymphocytic antibodies and marrow transplantation. VII. Two of nine monoclonal anti-Thy-1 antibodies used for pretreatment of donor marrow suppressed graft-versus-host reactions without added complement. (1985) (16)
Purging in auto- and allografts: monoclonal antibodies which use human complement and other natural effector mechanisms. (1990) (16)
Characterization of effector cells of graft vs leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia (2005) (16)
A noncomitogenic CD2R monoclonal antibody induces apoptosis of activated T cells by a CD95/CD95-L-dependent pathway. (1998) (16)
Probing dendritic cell function by guiding the differentiation of embryonic stem cells. (2003) (16)
Anti‐CD3 treatment up‐regulates programmed cell death protein‐1 expression on activated effector T cells and severely impairs their inflammatory capacity (2017) (16)
What can be done to prevent graft versus host disease? (1994) (15)
Gene Expression in the Gitr Locus Is Regulated by NF-κB and Foxp3 through an Enhancer (2014) (15)
Monoclonal antibody H 9/25 reacts with functional subsets of T and B cells: killer, killer precursor and plaque‐forming cells (1980) (15)
Stability of tolerance in mice generated by CD4 and CD8 monoclonal antibody treatment: cell transfer experiments. (1993) (15)
Regulatory T cells: context matters. (2009) (15)
Sequence of a rat immunoglobulin y2c heavy chain constant region cDNA: extensive homology to mouse y3 (1988) (14)
Induced Foxp3+ T Cells Colonizing Tolerated Allografts Exhibit the Hypomethylation Pattern Typical of Mature Regulatory T Cells (2016) (14)
Cell- and tissue-specific expression of a human CD59 minigene in transgenic mice. (1994) (14)
Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease (2014) (14)
T cell dependence of B cell unresponsiveness in vitro (1974) (14)
CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic. (2012) (14)
Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways. (1987) (14)
Specificity of monoclonal antibody Campath-1. (1988) (14)
Mechanisms of immunological tolerance. (2016) (14)
Esophageal webs. (1957) (14)
The inter-relationship of antigenic structure, thymus-independence and adjuvanticity. IV. A general model for B-cell induction. (1975) (14)
Detection of monoclonal antibodies against cell surface antigens: the use of antiglobulins coupled to red blood cells. (1984) (14)
T cell-dependent mediator and B-cell clones. (1975) (13)
Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies. (1994) (13)
Monoclonal antibodies for immunosuppression. (1988) (13)
Erythroid-specific expression of human CD59 and transfer to vascular endothelial cells. (1994) (13)
Cell replacement therapy and the evasion of destructive immunity (2007) (13)
Sparing of first dose effect of monovalent anti-CD3 antibody used in allograft rejection is associated with diminished release of pro-inflammatory cytokines. (1994) (13)
A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. (2008) (12)
Segregation of mouse hemopoietic progenitor cells using the monoclonal antibody, YBM/42 (1983) (12)
The new immunosuppression: just kill the T cell (2003) (12)
A humanized CD18 antibody can block function without cell destruction. (1993) (12)
Resistance of regulatory T cells to glucocorticoid-induced [corrected] TNFR family-related protein (GITR) during Plasmodium yoelii infection. (2005) (12)
Isolation and expression of cDNA encoding the canine CD4 and CD8α antigens (1994) (12)
Guiding Postablative Lymphocyte Reconstitution as a Route Toward Transplantation Tolerance (2014) (11)
Co-operation across histocompatibility differences. The role of inhibitory T cells in preventing successful T-B interaction. (1977) (11)
Immunosuppression with monoclonal antibodies--rules for effective serotherapy. (1985) (11)
Human monoclonal antibodies: the residual challenge of antibody immunogenicity. (2014) (11)
Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series. (1985) (11)
CAMPATH 1H (ALEMTUZUMAB) IN RENAL TRANSPLANTATION: 5-YEAR COMPARATIVE FOLLOW UP. (2004) (11)
Interactions between T and B Cells: A Review (1979) (10)
A novel role for Glucocorticoid-Induced TNF Receptor Ligand (Gitrl) in early embryonic zebrafish development. (2010) (10)
CD4 mAbs prevent progression of alloactivated CD4+ T cells into the S phase of the cell cycle without interfering with early activation signals. (1996) (10)
Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T-cell depletion. (1993) (10)
Tolerance induction in concordant heart-xenografted mice by CD4 and CD8 monoclonal antibodies. (1994) (10)
Monoclonal antibodies for organ transplantation: prospects for the future. (1988) (10)
Radiotherapy-based conditioning is effective immunosuppression for patients undergoing transplantation with T-cell depleted stem cell grafts for severe aplasia. (2004) (10)
Tolerance Induction Using CD4 and CD8 Monoclonal Antibodies (1989) (10)
Regaining self-control--regulation and immunotherapy. (1998) (10)
THERAPEUTIC POTENTIAL OF RAT MONOCLONAL ANTIBODIES: ISOTYPE WITH HUMAN LYMPHOCYTES SPECIFICITY OF ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY (1985) (10)
A non myeloablative regimen for allografting high-risk patients: Low toxicity, stable engraftment without GVHD, disease control and potential for GVL with adoptive immunotherapy. (1999) (10)
Limiting Dilution Analysis ofHelper T-cell Function (1975) (10)
Therapeutic potential of monoclonal antibodies to the leucocyte common antigen. (1985) (9)
Epstein-Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor. (1999) (9)
Reprogramming the immune system using antibodies. (2006) (9)
Genetic modification of dendritic cells through the directed differentiation of embryonic stem cells. (2007) (9)
Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H. (2001) (9)
Combination therapy with a TNF antagonist and a CD4 monoclonal antibody in rheumatoid arthritis. A pilot study. (1997) (9)
ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS (1994) (9)
Limiting Dilution Analysis (1998) (9)
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis (2005) (8)
Double T cell depletion of bone marrow using sequential positive and negative cell immunoaffinity or CD34+ cell selection followed by Campath-1M; effect on CD34+ cells and progenitor cell recoveries (1998) (8)
Special regulatory T cell review: The suppression problem! (2008) (8)
The effect on the growth of BP8 ascites tumour in C3H-C57 or C3H mice of "lymphocyte preparations" from C57 mice injected with BP8 cells and Freund's adjuvant. (1967) (8)
Unrelated donor bone marrow transplant in childhood ALL. The role of T-cell depletion. (1996) (8)
High dose bone marrow transplantation induces deletion of antigen-specific T cells in a Fas-independent manner. (2000) (8)
Extrathymic signals regulate the onset of T cell repertoire selection (2000) (8)
Non-Invasive Multiphoton Imaging of Islets Transplanted Into the Pinna of the NOD Mouse Ear Reveals the Immediate Effect of Anti-CD3 Treatment in Autoimmune Diabetes (2018) (8)
Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance. (2001) (8)
Selective isolation of murine erythropoietin-responsive progenitor cells (CFU-E) with monoclonal antibodies. (1983) (7)
Tolerance Induction in the Peripheral Immune System (1993) (7)
Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL). (2001) (7)
Coreceptor blockade targeting CD4 and CD8 allows acceptance of allogeneic human pluripotent stem cell grafts in humanized mice. (2020) (7)
T cell help mechanisms in the in vitro antibody response: the role of linked and non-linked recognition interactions. (1984) (7)
Tolerance induction with CD4 monoclonal antibodies. (1998) (7)
Preservation of recall immunity in anti‐CD3‐treated recent onset type 1 diabetes patients (2011) (7)
Human Complement-Fixing Antibodies in Transplantation (1985) (7)
How may immunosuppression lead to tolerance? The war analogy (1996) (7)
Prophylactic use of an antilymphocyte monoclonal antibody following renal transplantation: a randomized controlled trial. (1987) (7)
The new immunosuppression: intervention at the dendritic cell-T-cell interface. (2005) (7)
The failure to show a necessary role for C3 in the in vitro antibody response. (1975) (7)
Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma. (1999) (6)
Approaching Tolerance in Transplantation (2001) (6)
CD 8 Lymphocytes Do Not Mediate Protection against Acute Superinfection 20 Days after Vaccination with a Live Attenuated Simian Immunodeficiency Virus (2005) (6)
CD4+ T Cell Fate Decisions Are Stochastic, Precede Cell Division, Depend on GITR Co-Stimulation, and Are Associated With Uropodium Development (2018) (6)
Long term results of reduced intensity transplantation in multiply relapsed and refractory Hodgkin's lymphoma: Evidence of a therapeutically relevant graft-versus-lymphoma effect. (2003) (6)
The use of monoclonal antibodies against activated human T cells following renal allografting in the baboon. (1987) (6)
Loss of the TGF beta-activating integrin alpha v beta 8 on dendritic cells protects mice from chronic intestinal parasitic infection via control of type 2 immunity (2013) (6)
Differences in calcium requirements for B-cell tolerance and immunity. (1980) (6)
Evidence for the inactivation of precursor B cells in high dose unresponsiveness (1976) (6)
The 'intrinsic adjuvanticity' and immunogenicity of trinitrophenylated lipopolysaccharide. (1975) (6)
Can B-cell tolerance be induced by oligovalent thymus dependent antigens? (1977) (6)
Dominant regulation (1999) (6)
In vitro and in vivo depletion of T cells. (1993) (6)
A Bacterial Artificial Chromosome Reporter System for Expression of the Human FOXP3 Gene in Mouse Regulatory T-Cells (2017) (5)
CD52-Negative NK Cells Are Abundant in the Liver and Less Susceptible to Alemtuzumab Treatment (2016) (5)
Interaction of rat monoclonal antibodies with human killer cells. (1984) (5)
CD4 and CD8 monoclonal antibody therapy: Strategies to prolong renal allograft survival in the dog (1993) (5)
Infectious tolerance. What are we missing? (2020) (4)
Monoclonal antibodies for the depletion of specific subpopulations of lymphocytes. (1987) (4)
Non-myeloablative conditioning limits transplant related mortality in patients who have previously failed high dose treatment. (2000) (4)
MONOCLONAL-ANTIBODIES THAT RECOGNIZE ACTIVATED HUMAN-LYMPHOCYTES - EXPERIMENTAL AND CLINICAL-STUDIES (1988) (4)
Drug minimization in transplantation: an opinion. (2014) (4)
Regulation and privilege in transplantation (2007) (4)
Use of Ceprate CD34-positive selection system for depletion of T cells in allogeneic transplantation (1997) (4)
Combined use of RS61443 with CD4 and CD8 MAbs to generate tolerance to skin xenografts from rat to mouse. (1994) (4)
MS 4 A 4 B Is a GITR-Associated Membrane Adapter , Expressed by Regulatory T Cells , Which Modulates T Cell Activation 1 (2009) (4)
Non-myeloablative transplantation for patients with Hodgkin's disease: Limited transplant related mortality and possible evidence of a graft versus Hodgkin's effect. (2001) (4)
Is tolerance therapy a plausible possibility? (1991) (4)
Non-myeloablative allogeneic transplantation for high-risk acute leukemia and myelodysplasia. (2001) (4)
The influence of antigen presentation on the generation of T-helper cells with different functions. (1977) (4)
INTERACTION OF MONOCLONAL-ANTIBODIES WITH THE IMMUNE-SYSTEM (1986) (4)
Immune reconstitution following allogeneic bone marrow transplantation depleted of T-cells. (1998) (4)
Development and clinical use of CAMPATH® 1H (2003) (3)
Monoclonal antibodies for the therapeutic induction of tolerance. (1993) (3)
Immunosuppression with monoclonal antibodies: some speculations about tolerance in the context of tissue grafting. (1988) (3)
HISTOCOMPATIBLE UNRELATED VOLUNTEER DONORS FOR BMT IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA (1988) (3)
Allosuppression: evidence for the involvement of both “noncytotoxic” and cytotoxic T cells (1984) (3)
Haemopoietic progenitor cell heterogeneity revealed by a single monoclonal antibody, YW 13.1.1. (1984) (3)
B Cell Activation (1975) (3)
The evolution of therapeutic antibodies (2020) (3)
Correction: Secreted and Transmembrane 1A Is a Novel Co-Stimulatory Ligand (2013) (3)
THERAPY WITH HYBRID ANTIBODIES (1989) (3)
Transplantation tolerance: the big picture. Where do we stand, where should we go? (2017) (3)
Direct antibody rosette-forming reactions using monoclonal markers of lymphocyte subpopulations. Methodology and applications illustrated by investigations with rat pan-T antibodies of the CAMPATH series. (1986) (3)
INFLUENCE OF ISOTYPE ON SUPPRESSION OF GVH WITH ANTI-TH-1 (1984) (3)
Regulatory T cells and transplantation tolerance: Emerging from the darkness? (2021) (3)
ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES (1993) (3)
Prospects for ensuring acceptance of ES cell-derived tissues (2010) (3)
Identification of cells of the human mononuclear phagocyte system with rat monoclonal antibodies (1987) (3)
Transplantation regulating the rejection process: the search for new targets to minimise immunosuppressive therapy - Editorial overview (2003) (3)
Tolerance induction in the adult: 'danger' at Le Bischenberg. (1995) (3)
In vitro Treatment of Marrow with ATCG or Campath-1 for Prophylaxis of GVHD (1985) (3)
reconstitution cell transplantation: potential role of Campath-1H in delaying immune High incidence of cytomegalovirus infection after nonmyeloablative stem (2008) (3)
BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC MYELOID-LEUKEMIA (CML) USING MATCHED UNRELATED DONORS (1988) (2)
INVITRO TREATMENT OF MARROW WITH ATCG OR CAMPATH-1 FOR PROPHYLAXIS OF GVHD - RESULTS OF THE AG-KMT MUNCHEN (1985) (2)
Pediatric immunohematopoietic stem cell transplantation at a tertiary care center in Cape Town. (2008) (2)
The Monogamous T helper cell (1979) (2)
CD4 monoclonal antibodies in the preclinical dog renal allograft model. (1993) (2)
Transplantation - Editorial overview (1994) (2)
Reshaping a therapeutic CD 4 antibody (2)
Favourable Impact on Acute and Chronic Graft-Versus-Host Disease with Cyclophosphamide and In-Vivo Anti-CD52 Monoclonal Antibodies for Marrow Transplantation from HLA-Identical Sibling Donors for Acquired Aplastic Anaemia. (2004) (2)
Isolation and expression of cDNA encoding the canine CD4 and CD8 alpha antigens. (1994) (2)
A non-myeloablative regimen with minimal non relapse mortality for allografting patients with Hodgkin's disease (2001) (2)
A step closer to effective transplant tolerance? (2012) (2)
Activation rather than Foxp3 expression determines that TGF‐β‐induced regulatory T cells out‐compete naïve T cells in dendritic cell clustering (2012) (2)
Therapy with Monoclonal Antibodies. II. The Contribution of Fcγ Receptor Binding and the Influence of CH1 and CH3 Domains on In Vivo Effector Function (1998) (2)
The use of non-depleting anti-CD4 monoclonal antibody for immune tolerance induction in Pompe disease (2012) (2)
CD4 and CD8 monoclonal antibody therapy in the dog: strategies to induce tolerance to renal allografts. (1995) (2)
CAMPATH-1H exposes three mechanisms underlying the natural history of multiple sclerosis in the individual patient (1998) (2)
DIABETIC STUDIES The Review of Chapter IV . 2 CD 3 Monoclonal Antibodies : A First Step Towards Operational Immune Tolerance in the Clinic (2013) (2)
SAGE analysis of cell types involved in tolerance induction. (2007) (2)
The induction and Maintenance of Transplant Tolerance engages Both regulatory and anergic cD 4 + T cells (2019) (2)
Robert Royston Amos (Robin) Coombs. 9 January 1921 — 25 January 2006 (2009) (2)
Antiadhesion Molecule Therapy for Refractory Vasculitis: Experience in Five Patients Treated with Humanised Monoclonal anti CD18 Antibodies (1999) (2)
Seltene Differentialdiagnose eines thorakalen Rundherdes (1996) (2)
Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease. (1988) (2)
Ex vivo T-cell depletion of bone marrow grafts with campath 1 prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation. (1997) (2)
Autografting with CD52 monoclonal antibody-purged marrow for acute lymphoblastic leukemia. (1996) (2)
THE MECHANISM OF ACTION OF PROTECTIN (CD59), A HOMOLOGOUS RESTRICTION FACTOR OF THE HUMAN-COMPLEMENT SYSTEM (1990) (2)
Aglycosyl anti-CD3 monoclonal antibody therapy in rheumatoid arthritis - Results of a pilot safety study (2005) (2)
PROPE (ALMOST) TOLERANCE USING CAMPATH 1H INDUCTION AND LOW-DOSE CYCLOSPORIN MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS, A FOLLOW-UP OF 7 TO 21 MONTHS (1999) (2)
CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP) (1993) (2)
Monoclonals and marrow transplants (1986) (2)
The role of MHC gene products in the development of the T-cell repertoire. (1980) (2)
Transplantation—caught in the crossfire! (2002) (2)
LEUKAEMIC RELAPSE AFTER CAMPATH 1-TREATED BONE-MARROW TRANSPLANTATION FOR LEUKAEMIA (1987) (2)
Production, selection, and testing of monoclonal antibodies to canine leukocytes in the dog kidney allograft model. (1994) (1)
The role of the major histocompatibility complex in in vitro antibody responses; MHC restriction in responses involving linked recognition of antigenic determinants is not solely consequent to T cell-accessory cell restrictions. (1984) (1)
Neutralising TNF activity leads to remission in refractory posterior non-infectious uveitis (2004) (1)
Monoclonal antibody targeting of CD4(+) and CD8(+) cells for prolongation of baboon renal allograft survival. (2005) (1)
Reduced incidence of GVHD in recipients of t-cell depleted marrow (1986) (1)
BIOLOGICAL EFFECTS OF A HUMAN IGG4 MONOCLONAL-ANTIBODY IN-VIVO (1995) (1)
Immunological Tolerance (2010) (1)
Apoptosis, tolerance and immunoregulation - Integrated pathways for immune system homeostasis (1998) (1)
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis (2004) (1)
Plenary Session 3: Found in Translation: Learning Immunology from Human Therapeutic Trials (2011) (1)
Pharmacologically Modified Dendritic Cells: A Route to Tolerance‐associated Genes (2008) (1)
A study of regulatory T cells in allogeneic haematopoietic stem cell transplantation (2012) (1)
MONOCLONAL-ANTIBODIES CAN BE USED TO CONTROL BOTH GVHD AND REJECTION IN MOUSE MODELS OF BONE-MARROW TRANSPLANTATION (1985) (1)
Induction of durable, antigen specific tolerance in primates with a short therapeutic course of non-depleting Anti-CD4 antibody. (2002) (1)
HUMANIZED MONOCLONAL-ANTIBODY (MAB) THERAPY FOR WEGENERS GRANULOMATOSIS (WG) (1995) (1)
RESPONSES WITH MONOCLONAL ANTIBODIES (1989) (1)
Corrigendum: Therapeutic potential of monovalent monoclonal antibodies (1984) (1)
Early infiltration of allografts by a subset of host mononuclear cells bearing inhibitory Ly49 receptors determines development of allograft rejection or tolerance. (2005) (1)
Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation. (2000) (1)
CD 4 and CD 8 monoclonal antibody therapy in canine renal allografts (1994) (1)
Phage-display library selection and mutation for the engineering of antibody affinity (1996) (1)
Prospects for the application of antibodies in medicine. (2000) (1)
Antibody immunogenicity: does bioprocessing hold all the answers? (2015) (1)
Induction of Immunological Tolerance as a Therapeutic Procedure. (2016) (1)
Therapeutic immunosuppression of T cells. (1992) (1)
Transplantation Tolerance Regulatory Cells Mediate Dominant - CD25 + and CD4 + CD25 + Both CD4 (2010) (1)
MCABS OF THERAPEUTIC POTENTIAL WHICH INTERACT WITH HOST EFFECTOR SYSTEMS (1984) (1)
HUMANIZED MONOCLONAL-ANTIBODY THERAPY FOR SYSTEMIC VASCULITIS (1993) (1)
(5) Induction of remission in systemic vasculitis with monoclonal antibody Campath‐1H (1989) (1)
[Surgery of the gallbladder and bile ducts in the aged]. (1984) (1)
EIN ARCHIMYSTES IN SAGALASSOS (1978) (1)
B and T cells in immune recognition: Edited by F. Loor and G.E. Roelands, Pp. 504. John Wiley & Sons Ltd. 1977. £18.50 (1977) (1)
AN IN-VIVO MODEL FOR DETERMINING RULES OF ANTIBODY DESIGN (1994) (1)
EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY (1988) (1)
Availability of Campath-1 antibodies for bone marrow transplantation. (1995) (1)
INSITU ANALYSIS OF THYROID T-CELL INFILTRATES IN MURINE EXPERIMENTAL AUTOIMMUNE-THYROIDITIS (EAT) (1987) (1)
Preventing the immunogenicity of biological therapies (2011) (0)
USING A CDw52 SPECIFIC ANTIBODY FOR TREATING BY T-CELLS MEDIATED arthritis (1992) (0)
Tolerance and transplantation (SY2-4) Chairpersons: Mitsuru Matsumoto, Kathryn Wood (2010) (0)
T-cell depletion of peripheral blood progenitor cell grafts is associated with effective protection from GVHD and rapid haematopoietic reconstitution. (1997) (0)
CD40 Ligand Blockade Induces CD4 (1999) (0)
Immune reconstitution post T-CELL depleted allogeneic bone marrow transplantation (1998) (0)
In marrow aplasia reduced-intensity conditioning and T-cell depletion of cytokine mobilised stem cells provides good engraftment without GvHD (2006) (0)
Antigen recognition in the immune system (2020) (0)
Survival of patients after lymphocytotoxic monoclonal antibody therapy for RA. (1998) (0)
In vivo/ex vivo T-cell depletion with anti-CD52 monoclonal antibodies: long-term results in patients with acute leukaemia in CR1 (2004) (0)
nonmyeloablative stem cell transplantation In vivo CAMPATH-1H prevents graft-versus-host disease following (2013) (0)
Introduction to the immune system (2020) (0)
Indirect Recognition Graft Rejection Can Operate Through Cutting Edge: Linked Suppression of Skin (1998) (0)
CELL CONTACT IS NECESSARY FOR COOPERATION BETWEEN T AND B MEMORY CELLS (1980) (0)
Adoptive suppression of erythrocyte autoantibodies in Lyt-2+ depleted recipients. (1989) (0)
therapeutic antibodies and induce tolerance. (2001) (0)
In vivo kinetics of GITR, GITR-L expression and their functional significance in regulating viral immunopathology (2005) (0)
Immunomodulation of dog islets using a cocktail of monoclonal antibodies. (1992) (0)
Tolerance and Linked Suppression CD40 Ligand Blockade Induces CD4+ T Cell (2013) (0)
217 The adenosine-generating ecto-enzyme CD73 regulates human hair growth (2016) (0)
BONE-MARROW TRANSPLANTATION USING UNRELATED DONORS FOR CML IN CHRONIC PHASE (1991) (0)
with a Nondepleting CD4 Antibody Tolerance/Hyporesponsiveness in Baboons Induction of Immunological (2004) (0)
Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience (2003) (0)
Not glycosylated anti-CD3 IgG antibodies (1992) (0)
RESULTS OF T-CELL DEPLETION WITH CAMPATH-1 IN BONE-MARROW TRANSPLANTATION (BMT) FOR CHRONIC GRANULOCYTIC-LEUKEMIA (CGL) (1985) (0)
490. Successful Readministration of AAV8 Following Administration of Nondepleting CD4 Antibody at the Time of Vector Administration (2006) (0)
Dendritic Cells and Transplantation Tolerance (2008) (0)
EVALUATION OF OUTCOME AND CHIMERIC STATUS FOLLOWING HLA IDENTICAL SIBLING BONE-MARROW TRANSPLANTATION FOR SEVERE APLASTIC-ANEMIA USING IN-VIVO CAMPATH-1G (1995) (0)
Validation of Anti-Idiotypic Bridging ELISA to Quantitate TRX4 (Anti-Human CD3) Mab Levels in Human Serum (2007) (0)
ADOPTIVE SUPPRESSION OF ERYTHROCYTE RECIPIENTS AUTOANTIBODIES IN Lyt-2' DEPLETED (1989) (0)
THERAPEUTIC ANTIBODY STRUCTURES OF RAT AND HUMANIZED (CAMPATH-1) Fab FRAGMENTS (1996) (0)
Excessive T-cell depletion adversely affects transplant-related mortality following allogeneic stem cell transplantation. (2000) (0)
BONE-MARROW TRANSPLANTATION FOR CHRONIC PHASE CML - THE ROLE OF T-CELL DEPLETION IN 1988 (1988) (0)
Preliminary results of an non-myeloablative conditioning regimen for allogeneic stem cell transplantation. (1999) (0)
The TGF beta-activating integrin alpha v beta 8 on dendritic cells regulates type 2 immunity in the intestine to promote chronic parasitic infection (2013) (0)
Problems of output limits of large fossil fuel fired steam generators. I (1977) (0)
GENERATION AND FUNCTIONAL-CHARACTERIZATION OF A HUMANIZED ANTI-CD28 MONOCLONAL-ANTIBODY (1994) (0)
Inflammation, Demyelination, and Axonal Degeneration: Three Aspects of the Pathogenesis of Multiple Sclerosis Revealed by Campath-1H Treatment (2004) (0)
MATCHED UNRELATED DONOR BMT FOR CML - COMPARISON OF EXVIVO AND INVIVO T-CELL DEPLETION (1992) (0)
Contact Between Good Friends: What Limiting Dilution Analysis Taught Us (2005) (0)
CDR exchanged humanized chimeric T cell antibody. (1992) (0)
RAT MONOCLONAL-ANTIBODIES TO PREVENT G-VS-H AND H-VS-G REACTIONS IN BONE-MARROW TRANSPLANTATION (1986) (0)
THE ROLE OF INHIBITORY T CELLS IN PREVENTING T-B CO-OPERATION BETWEEN HISTOINCOMPATIBLE CELLS (1978) (0)
Metabolic aspects underlying immune regulation (2011) (0)
The quality of bone marrow induced peripheral T cell tolerance depends on the dose of bone marrow inoculum (1997) (0)
Monoclonal antibodies for conditioning prior to marrow transplantation (1989) (0)
Induction of immunological to a therapeutic antibody using variants of said therapeutic antibody tolerance. (1997) (0)
Immunomodulation of dog islets using a cocktail of monoclonal antibodies (1992) (0)
monoclonal antibodies Separation of hemopoietic cells from adult mouse marrow by use of (2011) (0)
The molecular mechanisms of regulatoryT cell immunosuppression (2011) (0)
Development and Clinical Experience with Humanised Monoclonal Antibodies (1990) (0)
(anti-CD40L) monoclonal antibody under nonmyeloablative conditions Requirements for the promotion of allogeneic engraftment by anti-CD154 (2013) (0)
Advances in the applications of monoclonal antibodies in clinical oncology. London, 28-30 May 1986. (1986) (0)
Monoclonal antibodies to induce therapeutic immunological tolerance (2019) (0)
Cobbold Elizabeth Adams Luis Graca Stephen Daley Stephen Yates Alison Paterson (2006) (0)
Anticorps pour l'antigene campath-1 (1989) (0)
Synergistic monoclonal antibodies for in vitro immunomodulation of dog islets. (1992) (0)
Overcome It T Cell Depletion and Approaches to Accelerated Memory Cell Homeostasis during (2006) (0)
The Nature of MHC Restrictions in T-B Cooperation (1978) (0)
Long-term outcome after marrow transplantation from HLA-identical sibling donors for acquired aplastic anaemia using cyclophosphamide and in-vivo anti-CD52 monoclonal antibodies (2005) (0)
1990 AAAS Philip Hauge Abelson Prize. (1990) (0)
In vivo Visualisation of Cytotoxic T Cell Activation and Differentiation during Allograft Rejection (1999) (0)
Anti-CD4 monoclonal antibody/tumour necrosis factor α inhibitors (2008) (0)
Tolerance induction by monoclonal CD3 antibodies is dependent on indoleamine 2,3 dioxygenase (IDO) (56.5) (2012) (0)
Reprogramming the immune system: a possible therapeutic approach to established autoimmune disease. (1993) (0)
Book reviews (1991) (0)
Harmless Antigen Cells following Prolonged Exposure to a Generation of Anergic and Regulatory T (2004) (0)
Immunogenicity of Biological Therapies A Novel Strategy To Reduce the (2010) (0)
cd4 specific monoclonal antibodies and which do not cause depletion, intended for the treatment of insulin dependent diabetes mellitus (idmm). (1992) (0)
THE NATURE OF AUTOIMMUNE-DISEASE - GENERAL DISCUSSION (1987) (0)
ROLE OF INHIBITOR T-CELLS IN PREVENTING SUCCESSFUL COOPERATION BETWEEN T AND B CELLS HISTOINCOMPATIBLE FOR PORTIONS OF MHC COMPLEX OTHER THAN I-A (1977) (0)
Enhanced Production of IL-10 by Dendritic (2005) (0)
REQUIREMENT FOR CD 4 AND CD 8 T-CELLS FOR TRANSFER OF SIALITIS IN NOD MICE (1988) (0)
THE ANTIBODY PROBLEM AND THE GENERATION OF MONOCLONAL ANTIBODIES (2011) (0)
Islet allografting in the dog model: potential therapies for tolerance induction. (1995) (0)
ROLE OF LYMPHOCYTES-T IN PROTECTION AGAINST MYCOBACTERIUM-TUBERCULOSIS (1986) (0)
Harnessing tolerance mechanisms with monoclonal antibodies (2007) (0)
Herman Waldmann, FRS, FRCP, FMEDSci: Emeritus Professor of Pathology, Sir William Dunn School of Pathology, University of Oxford, United Kingdom. (2018) (0)
The TGFβ-activating integrin αvβ8 on dendritic cells regulates type 2 immunity in the intestine to promote chronic parasitic infection (P3318) (2013) (0)
2. PROPE TOLERANCE WITH INDUCTION USING CAMPATH 1H AND LOW-DOSE CYCLOSPORIN MONOTHERAPY IN 31 CADAVERIC RENAL ALLOGRAFT RECIPIENTS( 未来のための今 : 移植-次世紀への新たなるアプロ-チ) (2000) (0)
The induction of transplantation tissue tolerance requires Foxp3 expression (2013) (0)
Candida albicans evades protective immunity by promoting the expansion of induced CD4(+) CD25(+) FoxP3(+) Helioslo regulatory T cells that enhance Th17 responses (2012) (0)
Title Minimum Information about T Regulatory Cells : A Step toward Reproducibility and Standardization Permalink (2018) (0)
EFFECT OF MONOCLONAL-ANTIBODIES TO LYMPHOCYTES-T ON THE DEVELOPMENT OF LOW-DOSE STREPTOZOTOCIN DIABETES (1986) (0)
TransplantationAntibodies Induce Infectious Cutting Edge : Anti-CD 154 Therapeutic Cobbold and (2000) (0)
Single-cell transcriptomics reveal that PD-1 mediates immune tolerance by regulating proliferation of regulatory T cells (2018) (0)
CD 95 / CD 95-L-Dependent Pathway Induces Apoptosis of Activated T Cells by a A Noncomitogenic CD 2 R Monoclonal Antibody Bismuth (1998) (0)
Transplantation of immunomodulated dog islets. (1994) (0)
Monoclonal antibody to induce tolerance (1990) (0)
Selective Depletion of Alloreactive Cells in Transplantation (1993) (0)
Donor-specific transplantation tolerance: The paradoxical behavior of CD4 (cid:1) CD25 (cid:1) T cells (2004) (0)
Directed differentiaion of dendritic cells from mouse embryonic stem cells: a novel tool for identifying targets for immunotherapy (2001) (0)
Regulation of the immune response. (2010) (0)
Antibodies and fragments of antibodies, compositions comprising these, the use of these for the preparation of medicaments as well as cell lines that express these (1989) (0)
Non-depleting antibodies TRX-1 to CD4 and its uses (2002) (0)
Allogeneic stem cell transplantation for lymphoproliferative disease using BEAM-Campath conditioning: An effective regime with low procedure-related toxicity. (1999) (0)
COMBINED USE OF CAMPATH-1G IN-VIVO AND IN THE BAG IN ALLOGENEIC BONE-MARROW TRANSPLANTATION (1993) (0)
MONOCLONAL-ANTIBODIES IN SYSTEMIC VASCULITIS - LONG-TERM BENEFIT FROM SHORT-TERM THERAPY (1993) (0)
Aglycosylated IgG anti-CD3 antibody. (1992) (0)
THE USE OF MONOCLONAL ANTILYMPHOCYTE ANTIBODIES IN CLINICAL IMMUNOSUPPRESSION (1985) (0)
Sequence of a rat immunoglobulin gamma 2c heavy chain constant region cDNA: extensive homology to mouse gamma 3. (1988) (0)
Advances in the applications of monoclonal antibodies in clinical oncology 25/27 may 1988. Abstracts of the proceedings (1989) (0)
Reprogramming the immune system. (2002) (0)
Research data supporting publication - title to be confirmed. (2016) (0)
Anti-inflammatory peripheral adenosine generation by leukocytes is tightly regulated by TGF-beta and is independent of Foxp3 (2010) (0)
Defining human T lymphocyte subsets using putative markers derived from mouse sage libraries (2004) (0)
Monoclonal antibody therapy in systemic vasculits (1990) (0)
CAMPATH 1H INDUCTION IMMUNOSUPPRESSION IN LIVER TRANSPLANTATION: 6 YEAR FOLLOW UP (2004) (0)
Figure 2, Immunoregulation by regulatory T cells (Treg). (2010) (0)
Inhibiting tumour necrosis factor (TNF) modulates chorioretinal infiltrating T cell phenotype in experimental autoimmune uveoretinitis (EAU). (1997) (0)
Myeloablative conditioning is well tolerated by older patients receiving T-cell depleted grafts (2005) (0)
Book reviews (1989) (0)
T-cell depletion of stem cell grafts with campath-1H "in the bag" followed by cyclosporin immunosuppression remains a cost effective strategy in transplantation (2004) (0)
COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H (1994) (0)
Protection by allogeneic lymphocytes from immunised donors against fatal challenge with bp8 ascotes tumour cells. (1966) (0)
Elimination of the Immunogenicity of Therapeutic Antibodies 1 (1999) (0)
ALTERED DEVELOPMENT OF ADOPTIVELY TRANSFERRED EXPERIMENTAL AUTOIMMUNE-THYROIDITIS (EAT) BY RAT MONOCLONAL-ANTIBODIES (MAB) TO L3T4 AND LYT-2 ANTIGENS (1988) (0)
Improvements relating to antibodies. (1989) (0)
ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO (1989) (0)
The contribution of Foxp3 and TGF beta to the iTreg proteome (2013) (0)
Human Immunogenetics edited by Stephen Litwin, Dekker, 1989. $150.00 (USA and Canada), $180.00 (all other countries) (856 pages) ISBN 0 8247 7899 5 (1989) (0)
Deciphering thymic development (2014) (0)
ANTIBODY TO CAMPATH-1H HUMANIZED FAB (1999) (0)
[A new type of scissors for episiotomy]. (1958) (0)
Monoclonal antibodies to haemopoietic cells (1982) (0)
[Rare differential diagnosis of a thoracic coin lesion. Lateral thoracic meningocele]. (1996) (0)
Induction of immunological tolerance to a therapeutic antibody by variants of the therapeutic antibody (1997) (0)
How many T cells help one B cell? (1980) (0)
This information is current as Depending on the Dose Clonal Deletion or Infectious Tolerance Bone Marrow Transplantation Induces Either (1998) (0)
Substantial peripheral T-cell depletion before grafting is beneficial in islet transplantation. (1995) (0)
Robert Royston Amos (Robin) Coombs. 9 (2016) (0)
Resident intestinal bacteria promote IL-10 expression in T cells (2010) (0)
Plastic T Cells: Recycling Effector Functions? (2011) (0)
The lymphokines — biochemistry and biological activity: edited by John W. Hadden and William E. Stewart II, Humana Press, 1981. £40.50 (xv + 437 pages) ISBN 0 89 603 029 6 (1982) (0)
IMMUNOREGULATORY APPROACHES TO TREATMENT - FINAL GENERAL DISCUSSION (1987) (0)
Antibodies to Campath-1 (1989) (0)
Speciﬁc subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase (2004) (0)
Requirement for CD 8 Th 1 and Th 2 Cells : No + Monospecific CD 4 Rejection of HY Disparate Skin Grafts by Waldmann and (1998) (0)
The immunogenicity problem in antibody therapy (2007) (0)
Regulatory T cells (PP-045) (2010) (0)
Analysis of the mechanism of beta cell destruction in NOD mice (1990) (0)
Targeting CD4 for the induction of dominant tolerance (2008) (0)
Monoclonal antibodies to enable therapeutic tolerance to stem cell derived transplants? (2020) (0)
671 The adenosine-generating ecto-enzyme, CD73, functions as an intrafollicular regulator of human hair growth (2016) (0)
Recombinant Antibodies for Immunotherapy: Immune Privilege and Tolerance – Therapeutic Antibody Approaches (2009) (0)
Chantal Kuhn Promoting Immune Tolerance Human CD 3 Transgenic Mice : Preclinical Testing of Antibodies (2011) (0)
Defining and overcoming the immunological barriers to stem cell therapies. (2008) (0)
AntiCD3 treatment upregulates PD1 expression on activated effector T cells and severely impairs their inflammatory capacity (2017) (0)
T-Cell Regulation without Clonal Selection by Antigen? Polygamous Suppressor Cells and Monogamous Helper Cells at High Frequencies (2019) (0)
Tcell helpmechanisms intheinvitro antibody response:theroleoflinked andnon-linked recognition interactions (1984) (0)
Engagement of HLA class I α1 domain induces apoptosis of activated CD45RA+ T cells (1997) (0)
Cancer immunology (2019) (0)
Induction of Interleukin-10 expression by the commensal flora (2011) (0)
T-cell depletion of bone marrow grafts with Campath 1 ex vivo prevents graft-versus-host disease without abrogating the antileukaemic effect of transplantation (1997) (0)
CAMPATH-1G IGG2B RAT MONOCLONAL FAB (1999) (0)
malignancies: influence of antibody isotype Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid (2011) (0)
RESTRICTION IN COOPERATIVE FUNCTION OF SINGLE HELPER T-CELLS (1977) (0)
Regulatory T-cells in Therapeutic Transplantation Tolerance (2008) (0)
Figure 1, Reprogramming the immune system using ES cells. (2010) (0)
Outcome following T-cell depletion of allogeneic peripheral blood progenitor cells for transplantation (1997) (0)

This paper list is powered by the following services:

Other Resources About Herman Waldmann

en.wikipedia.org

What Schools Are Affiliated With Herman Waldmann?

Herman Waldmann is affiliated with the following schools: